Skip to content

E4 Pharmaceutical Consulting

E4 Biotechnology and Pharmaceutical Consulting. Providing product development (CMC), regulatory, QA/QC and project management support to companies developing new small-molecule drugs, biologics and medical devices.

Welcome!!

Categories

  • Regulatory (2)
    • Regulatory Strategy (1)
    • Regulatory Submissions (2)

E4 Pharmaceutical Consulting

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

RSS FDA News

  • Federal Judge Says FDA Can't Regulate Barium Product as a Drug
    A federal judge has ruled that the FDA can no longer regulate barium sulfate as a drug.
  • White House Supports Updated Grassley-Wyden Drug Pricing Package
    Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and ranking member Ron Wyden (D-Ore.) have updated their bipartisan drug pricing legislation with provisions to reduce out-of-pocket expenses — and President Trump has said he would sign it into law.
  • House Republicans Unveil Alternative to Pelosi’s H.R. 3
    Four high-ranking House Republicans introduced drug pricing legislation Monday designed to replace House Speaker Nancy Pelosi’s H.R. 3, a bill they dismissed as one-sided and doomed to fail.
  • Celltrion Healthcare Gets EU’s OK for Remsima SC to Treat Rheumatoid Arthritis
    CT-P13 was approved by the FDA in 2016 under the trade name Inflectra.
  • Bipartisan Lawmakers Begin Work on Cures 2.0
    Upton and DeGette are asking for public comment by Dec. 16 on what Cures 2.0 should include.

RSS Pharma Times

  • SMC green light for rare blood cancer treatment
    NHS funding was backed for four medicines
  • Private clinic launches UK’s first MRIdian radiotherapy machine
    NHS patients will be able to access the treatment via clinical trials
  • Healx, Boehringer link for rare neurological disease therapy
    The project will utilise Healx' AI-based drug discovery platform
  • RCEM’s winter data reveals much worse picture of A&E waits
    "We are clearly in the worst state we’ve ever been in as we enter the true winter season", says College president Dr Katherine Henderson.
  • Sanofi bulks up cancer offering with Synthorx buy
    The French drugmaker is spending around $2.5 billion on the deal
  • AZ’ Calquence boosts PFS in CLL patients
    The drug demonstrates “remarkable efficacy”, says AZ’ José Baselga
Proudly powered by WordPress / Theme: Shoreditch by Automattic.